Over the past two decades, we have seen tremendous changes in the world. The primary changes is in connectivity, resource access, communication, and global development. Now, we have blockchain, cryptocurrency, innovations in food, logistics and distribution of resources.
At the same time, we still have much to explore. We still have to look forward to venturing out into space and we must solve other problems that plague us. These problems range from health issues to resource issues and more.
One company, Gingko Bioworks is looking into creations and how it can create a platform that deals with various products and services at a cellular level. Here is what you need to know about Gingko Bioworks.
Using Biology To Synthetically Create Goods and Products
The firm has several foundries where it will conduct strain engineering, DNA synthesis and combine it with software and automation processes to collaborate with firms to conduct synthetic creation of goods and services.
The firm is interested in providing its platform to companies thus enabling it to get paid to create with its innovative process. Gingko Bioworks currently works with firms like Robertet and more to present solutions.
It has partnerships with companies ranging from Bayer to Motif Foods and projects like Joyn Bio that help the company to stand out. It notes that it works with over 100 cumulative customer programs across a wide range of end markets.
Gingko Bioworks is an interesting company because if it can continue to partner with large firms and work on other projects that allows it to develop companies, spin them out and have a stake in their progress, it could be extremely compelling.
Whether it is consumer technology, industrials and the environment, agriculture, food and nutrition, or pharma and biotech, the company has a bit of involvement in them.
Gingko Bioworks has the foundry revenue and the downstream value component that takes place in the form of royalties and also an equity stake component.
Innovation Is Always In Style
The current decade is going to be a very interesting one but it is unlikely to be like the previous decade. While there were different examples of excess, this decade seems to be one where everyone has to pay attention to costs and organize accordingly.
From energy problems in Asia and Europe to inflation issues across the world and other problems, companies are looking to be more fiscally conservative. Innovative companies that are burning cash will have to continue to show progress to sustain themselves or risk going bankrupt. They do have the option of being acquired by another entity as well.
This sector is heating up as industry heavyweights and startups continue to invest and focus on specific parts of life sciences.